Emergency rescue plan for cancer Treatment's dangerous side effects
NCT ID NCT05306080
Summary
This early-stage study is testing emergency rescue drugs for patients who develop severe, life-threatening immune reactions after receiving CAR-T cell cancer therapy. The study will enroll up to 10 adults already participating in CAR-T cell trials at the University of Pennsylvania. Researchers want to see if giving these rescue drugs is safe and practical when standard treatments for these dangerous side effects fail.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HLH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.